Sarah A Goldstein1, Cary C Ward2. 1. Duke University Medical Center, 2301 Erwin Rd, Box 2819, Durham, NC, 27710, USA. sarah.goldstein@duke.edu. 2. Duke University Medical Center, 2301 Erwin Rd, Box 2819, Durham, NC, 27710, USA.
Abstract
PURPOSE OF REVIEW: The number of pregnancies complicated by valvular heart disease is increasing. This review describes the hemodynamic effects of clinically important valvular abnormalities during pregnancy and reviews current guideline-driven management strategies. RECENT FINDINGS: Valvular heart disease in women of childbearing age is most commonly caused by congenital abnormalities and rheumatic heart disease. Regurgitant lesions are well tolerated, while stenotic lesions are associated with a higher risk of pregnancy-related complications. Management of symptomatic disease during pregnancy is primarily medical, with percutaneous interventions considered for refractory symptoms. Most guidelines addressing the management of valvular heart disease during pregnancy are based on case reports and observational studies. Additional investigation is required to further advance the care of this growing patient population.
PURPOSE OF REVIEW: The number of pregnancies complicated by valvular heart disease is increasing. This review describes the hemodynamic effects of clinically important valvular abnormalities during pregnancy and reviews current guideline-driven management strategies. RECENT FINDINGS:Valvular heart disease in women of childbearing age is most commonly caused by congenital abnormalities and rheumatic heart disease. Regurgitant lesions are well tolerated, while stenotic lesions are associated with a higher risk of pregnancy-related complications. Management of symptomatic disease during pregnancy is primarily medical, with percutaneous interventions considered for refractory symptoms. Most guidelines addressing the management of valvular heart disease during pregnancy are based on case reports and observational studies. Additional investigation is required to further advance the care of this growing patient population.
Authors: Sing-Chien Yap; Willem Drenthen; Petronella G Pieper; Philip Moons; Barbara J M Mulder; Bianca Mostert; Hubert W Vliegen; Arie P J van Dijk; Folkert J Meijboom; Eric A P Steegers; Jolien W Roos-Hesselink Journal: Int J Cardiol Date: 2007-05-04 Impact factor: 4.164
Authors: W Drenthen; P G Pieper; J W Roos-Hesselink; A C M Schmidt; B J M Mulder; A P J van Dijk; H W Vliegen; K M Sollie; A A Voors; T Ebels; D J van Veldhuisen Journal: Heart Date: 2006-07-03 Impact factor: 5.994
Authors: Stefan Orwat; Gerhard-Paul Diller; Iris M van Hagen; Renate Schmidt; Daniel Tobler; Matthias Greutmann; Regina Jonkaitiene; Amro Elnagar; Mark R Johnson; Roger Hall; Jolien W Roos-Hesselink; Helmut Baumgartner Journal: J Am Coll Cardiol Date: 2016-10-18 Impact factor: 24.094
Authors: Iris M van Hagen; Jolien W Roos-Hesselink; Titia P E Ruys; Waltraut M Merz; Sorel Goland; Harald Gabriel; Malgorzata Lelonek; Olga Trojnarska; Wael Abdulrahman Al Mahmeed; Hajnalka Olga Balint; Zeinab Ashour; Helmut Baumgartner; Eric Boersma; Mark R Johnson; Roger Hall Journal: Circulation Date: 2015-06-22 Impact factor: 29.690
Authors: Zachary L Steinberg; Clara P Dominguez-Islas; Catherine M Otto; Karen K Stout; Eric V Krieger Journal: J Am Coll Cardiol Date: 2017-06-06 Impact factor: 24.094